Camurus Provides Regulatory Update on the US NDA for CAM2029 (Oclaiz™) in Acromegaly

NDA FilingCRLCAM2029Oclaiz™Negative

AI Analysis

Summary

Camurus announced the FDA issued a complete response letter for the NDA of CAM2029 (Oclaiz™) in acromegaly, indicating additional information or changes are required before approval.

Outcome Details

FDA issued a complete response letter regarding the NDA for CAM2029

Importance:8/10

Sentiment:

-0.80

regulatoryFDANDACRLacromegaly

Related Companies

$CAMX

Read the original article

Published by Drugs.com New Drug Applications on June 10, 2026 2:06 AM

Read Original